Search Results

There are 5130 results for: content related to: Current and emerging targeted therapies for metastatic breast cancer

  1. Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration

    Journal of Pharmaceutical Sciences

    Volume 102, Issue 3, March 2013, Pages: 794–812, Zephania W. Kwong Glover, Lynn Gennaro, Sandeep Yadav, Barthélemy Demeule, Pin Yee Wong and Alavattam Sreedhara

    Version of Record online : 5 DEC 2012, DOI: 10.1002/jps.23403

  2. You have free access to this content
    Pertuzumab: A New Targeted Therapy for HER2-Positive Metastatic Breast Cancer

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 34, Issue 1, January 2014, Pages: 60–71, Stephanie J. Malenfant, Karen R. Eckmann and Chad M. Barnett

    Version of Record online : 5 AUG 2013, DOI: 10.1002/phar.1338

  3. You have free access to this content
    Management of patients with HER2-positive metastatic breast cancer: Is there an optimal sequence of HER2-directed approaches?


    Volume 121, Issue 1, January 1, 2015, Pages: 17–24, Amelia B. Zelnak and Kari B. Wisinski

    Version of Record online : 23 JUL 2014, DOI: 10.1002/cncr.28815

  4. You have free access to this content
    Management of patients treated with pertuzumab in the Australian clinical practice setting

    Asia-Pacific Journal of Clinical Oncology

    Volume 12, Issue S2, June 2016, Pages: 5–15, Natasha Woodward, Michelle White, Lina Pugliano, Daphne Tsoi and Caroline Ryan

    Version of Record online : 2 JUN 2016, DOI: 10.1111/ajco.12500

  5. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation

    Cell Proliferation

    Volume 40, Issue 4, August 2007, Pages: 488–507, G. Brockhoff, B. Heckel, E. Schmidt-Bruecken, M. Plander, F. Hofstaedter, A. Vollmann and S. Diermeier

    Version of Record online : 16 JUL 2007, DOI: 10.1111/j.1365-2184.2007.00449.x

  6. You have free access to this content
    Systemic treatment of HER2+ metastatic breast cancer: Clinical conundrums and future perspectives

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue S4, June 2014, Pages: 15–25, Richard De Boer, Jane Beith, Jacquie Chirgwin, Sue Chua, Maree Colosimo, Prudence Francis, Michael Green, Ken Pittman, Michelle White, Nicholas Wilcken, Nicholas Zdenkowski and Richard Bell

    Version of Record online : 6 MAY 2014, DOI: 10.1111/ajco.12207

  7. You have free access to this content
    Biomarkers of drugs targeting HER-family signalling in cancer

    The Journal of Pathology

    Volume 232, Issue 2, January 2014, Pages: 219–229, Filippo Montemurro and Maurizio Scaltriti

    Version of Record online : 10 DEC 2013, DOI: 10.1002/path.4269

  8. You have free access to this content
    Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors

    Cytometry Part A

    Volume 79A, Issue 9, September 2011, Pages: 684–693, Simone Diermeier-Daucher, Stefanie Breindl, Stefan Buchholz, Olaf Ortmann and Gero Brockhoff

    Version of Record online : 22 JUL 2011, DOI: 10.1002/cyto.a.21107

  9. You have free access to this content
    Systemic treatment of HER2-positive metastatic breast cancer: A systematic review

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue S4, June 2014, Pages: 1–14, Nicholas Wilcken, Nicholas Zdenkowski, Michelle White, Ray Snyder, Ken Pittman, Paul Mainwaring, Michael Green, Prudence Francis, Richard De Boer, Maree Colosimo, Sue Chua, Jacquie Chirgwin, Jane Beith and Richard Bell

    Version of Record online : 6 MAY 2014, DOI: 10.1111/ajco.12206

  10. You have full text access to this Open Access content
    Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer

    Cancer Science

    Volume 102, Issue 1, January 2011, Pages: 1–8, Toru Mukohara

    Version of Record online : 6 SEP 2010, DOI: 10.1111/j.1349-7006.2010.01711.x

  11. ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective

    Medicinal Research Reviews

    Volume 32, Issue 1, January 2012, Pages: 166–215, Ruchi Saxena and Anila Dwivedi

    Version of Record online : 25 OCT 2010, DOI: 10.1002/med.20209

  12. Imaging EGFR and HER2 by PET and SPECT: A Review

    Medicinal Research Reviews

    Volume 34, Issue 3, May 2014, Pages: 596–643, Emily B. Corcoran and Robert N. Hanson

    Version of Record online : 29 AUG 2013, DOI: 10.1002/med.21299

  13. Flow Cytometric FRET Analysis of erbB Receptor Interaction on a Cell-by-Cell Basis

    Annals of the New York Academy of Sciences

    Volume 1130, Issue 1, May 2008, Pages: 280–286, Simone Diermeier-Daucher, Max Hasmann and Gero Brockhoff

    Version of Record online : 28 JUN 2008, DOI: 10.1196/annals.1430.003

  14. Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

    Clinical Pharmacology in Drug Development

    Volume 2, Issue 1, January 2013, Pages: 11–24, Manish Gupta, Bei Wang, Timothy J. Carrothers, Patricia M. LoRusso, Yu-Waye Chu, Ted Shih, David Loecke, Amita Joshi, Ola Saad, Joo-Hee Yi and Sandhya Girish

    Version of Record online : 26 FEB 2013, DOI: 10.1002/cpdd.9

  15. You have free access to this content
    Trastuzumab-containing regimens for metastatic breast cancer

    Intervention Review

    The Cochrane Library

    Sara Balduzzi, Stefania Mantarro, Valentina Guarneri, Ludovica Tagliabue, Vanna Pistotti, Lorenzo Moja and Roberto D'Amico

    Published Online : 12 JUN 2014, DOI: 10.1002/14651858.CD006242.pub2

  16. You have free access to this content
    Systemic therapy for early-stage HER2-positive breast cancers: Time for a less-is-more approach?


    Volume 121, Issue 4, February 15, 2015, Pages: 517–526, Elisavet Paplomata, Rita Nahta and Ruth M. O'Regan

    Version of Record online : 24 OCT 2014, DOI: 10.1002/cncr.29060

  17. You have full text access to this OnlineOpen article
    Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines

    The Journal of Pathology

    Volume 229, Issue 3, February 2013, Pages: 390–399, Daniele Recupero, Lorenzo Daniele, Caterina Marchiò, Luca Molinaro, Isabella Castellano, Paola Cassoni, Alberto Righi, Filippo Montemurro, Piero Sismondi, Nicoletta Biglia, Giuseppe Viale, Mauro Risio and Anna Sapino

    Version of Record online : 13 DEC 2012, DOI: 10.1002/path.4074

  18. A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial


    Volume 122, Issue 19, October 1, 2016, Pages: 2961–2970, Jan C. Drooger, Harm van Tinteren, Steffen M. de Groot, Albert J. ten Tije, Hiltje de Graaf, Johanneke E. A. Portielje, Agnes Jager, Aafke Honkoop, Sabine C. Linn, Judith R. Kroep, Frans L. G. Erdkamp, Paul Hamberg, Alex L. T. Imholz, Quirine C. van Rossum-Schornagel, Joan B. Heijns, A. Elise van Leeuwen-Stok and Stefan Sleijfer

    Version of Record online : 17 JUN 2016, DOI: 10.1002/cncr.30141

  19. Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments


    Volume 56, Issue 5, April 2010, Pages: 560–572, Fabrício F T Barros, Desmond G Powe, Ian O Ellis and Andrew R Green

    Version of Record online : 30 MAR 2010, DOI: 10.1111/j.1365-2559.2010.03494.x

    Corrected by:


    Vol. 56, Issue 7, 986, Version of Record online: 7 JUN 2010

  20. You have free access to this content
    Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge

    European Journal of Heart Failure

    Volume 14, Issue 2, February 2012, Pages: 130–137, Carlo G. Tocchetti, Gianluca Ragone, Carmela Coppola, Domenica Rea, Giovanna Piscopo, Stefania Scala, Claudia De Lorenzo, Rosario V. Iaffaioli, Claudio Arra and Nicola Maurea

    Version of Record online : 18 FEB 2014, DOI: 10.1093/eurjhf/hfr165